Latest News and Press Releases

New York, USA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight The depression treatment market is...

Pune, India, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The treatment-resistant depression treatment market size is projected to grow from USD 1.95 billion in 2023 to USD 4.06 billion by 2030, exhibiting a...

New York, USA, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Treatment-Resistant Depression Market to Observe Stunning Growth by 2032, Assesses DelveInsight | Key Companies to Watch Out - Navitor, Supernus,...

Pune, India, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The global treatment-resistant depression treatment market size was valued at USD 1.52 billion in 2021. The market is projected to grow from USD 1.55...

Positive data from phase IIb study shows potential of COMP360 psilocybin therapy in treatment-resistant depression London, UK – 23 May 2022        COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a...

Positive early signals seen in two investigator-initiated studies presented at the Society of Biological Psychiatry Annual Meeting in New Orleans London, UK – 3 May 2022        COMPASS...

London, UK and New York, US, 19 January 2022  COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental...

Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January...

Matthew Owens appointed General Counsel and Chief Legal Officer; Lars Wilde, Chief Business Officer and Co-founder, to move into senior advisory role London, UK – 16 December...

Patients taking COMP360 psilocybin with concomitant SSRIs showed comparable treatment outcomes to patients withdrawn from their SSRI therapy in COMPASS’s phase IIb trialAll patients tolerated COMP360...